➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
AstraZeneca
Colorcon
Express Scripts
Dow

Last Updated: September 27, 2020

DrugPatentWatch Database Preview

Details for Patent: 9,327,114

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,327,114 protect, and when does it expire?

Patent 9,327,114 protects ZECUITY and is included in one NDA.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 9,327,114
Title:User-activated self-contained co-packaged iontophoretic drug delivery system
Abstract: A user-activated self-contained co-packaged iontophoretic drug delivery system and method of use for treatment of a subject are described.
Inventor(s): Sebree; Terri B. (Gladwyne, PA), Stathopulos; Robert P. (Boonton, NJ), Vinatoru; Mihai A. (Graham, NC)
Assignee: Teva Pharmaceuticals International GmbH (Rapperswil-Jona, CH)
Application Number:13/802,156
Patent Claim Types:
see list of patent claims
Compound; Delivery; Use; Formulation;

Drugs Protected by US Patent 9,327,114

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Teva Branded Pharm ZECUITY sumatriptan succinate SYSTEM;IONTOPHORESIS 202278-001 Jan 17, 2013 DISCN Yes No   Start Trial   Start Trial Y METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,327,114

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2011332187   Start Trial
Brazil 112013012117   Start Trial
Canada 2817824   Start Trial
China 103228318   Start Trial
Eurasian Patent Organization 026254   Start Trial
Eurasian Patent Organization 201390745   Start Trial
European Patent Office 2643048   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Harvard Business School
Moodys
Boehringer Ingelheim
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.